- Positive FDA Feedback to Progress Bexmarilimab
- Notice of Faron Pharmaceuticals Ltdâ€™s AGM
- FaronÂ´s Annual Report 2022 Published
- Financial Statement January 1 to December 31 2022
- Update to Faronâ€™s Financial Calendar for 2023
- Notice of 2022 Full-Year Results and Annual Report
- Holding(s) in Company
- Results of Placing
- Proposed Issue and Placing
- Price Monitoring Extension
Faron Pharmaceuticals Oy (4FR:FRA) closed at 3.58, 7.83% above its 52-week low of 3.32, set on Feb 10, 2023.
3.32Feb 10 20233.90Feb 17 2023
Short selling activityProvided by S&P Global Market Intelligence
|Market cap||200.33m GBP|
|EPS (TTM)||-0.4577 |
Data delayed at least 15 minutes, as of Mar 23 2023 07:04 BST.